Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD9574 + FPI-2265 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD9574 | AZD-9574|AZD 9574 | PARP-1 Inhibitor 13 | AZD9574 is a PARP1 inhibitor that can penetrate the blood-brain barrier, potentially leading to inhibition of tumor growth (PMID: 37967136). | |
| FPI-2265 | FPI 2265|FPI2265|225Ac-PSMA-I&T | FPI-2265 is a radioconjugate comprising the radionuclide actinium-225 linked to a monoclonal antibody that targets PSMA, which delivers radiation to PSMA-expressing tumor cells, potentially resulting in antitumor activity (Cancer Res (2024) 84 (7_Supplement): CT224). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|